Agensys, Inc.
Agensys, Inc., a subsidiary of Astellas Pharm
2225 Colorado Avenue
Santa Monica
California
90404
United States
Tel: 310-820-8029
Fax: 310-382-2802
Website: http://www.urogenesys.com/
Email: info@urogenesys.com
54 articles about Agensys, Inc.
-
Clinical Catch-Up: February 10-14
2/17/2020
It was a very busy week for clinical trial news. Here’s a look. -
U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication of MYCAMINE® (micafungin for injection) for the Treatment of Invasive Candidiasis in Pediatric Patients Less Than 4 Months of Age
1/8/2020
Astellas Pharma Inc. announced that the U.S. Food and Drug Administration has approved its supplemental New Drug Application for MYCAMINE® in support of the treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses without meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age.
-
FDA Clears Their Desk for the End-of-the-Year Push: Ebola, Urothelial Cancer, Compounding Drugs a...
12/20/2019
Moving into the holidays and the fast-approaching end of the year, the U.S. Food and Drug Administration (FDA) got busy wrapping up a number of to-do items. Here’s a look. -
The FDA granted Astellas Pharma and Seattle Genetics accelerated approval for Padcev, a first-of-its-kind treatment for adult patients with metastatic urothelial bladder cancer.
-
Astellas Oncology Announces Grand Prize Winner of 2019 C3 Prize® to Improve Cancer Care
10/28/2019
Astellas Pharma US, Inc. ("Astellas") today announced it has awarded $200,000 in total grants and resources to winners of the fourth annual C3 (Changing Cancer Care) Prize, a challenge that funds the best ideas beyond medicine to improve cancer care for patients, caregivers and their loved ones.
-
Astellas Oncology Announces 2019 C3 Prize® Finalists
9/30/2019
Astellas Pharma US, Inc. announced the finalists for its fourth annual C3 Prize, a challenge that funds the best ideas beyond medicine to improve cancer care for patients, caregivers and their loved ones.
-
Astellas Receives Positive CHMP Opinion for XOSPATA® (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
9/20/2019
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the oral once-daily therapy XOSPATA® (gilteritinib) as a monotherapy for the treatment of adult patients who have relapsed or refractory (resistant to treatment) acute myeloid leukemia (AML) with a FLT3 mutation (FLT3mut+).
-
Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
9/16/2019
Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for the investigational agent enfortumab vedotin
-
U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review for the Treatment of Men with Metastatic Hormone-Sensitive Prostate Cancer - Aug. 21, 2019
8/21/2019
XTANDI Supplemental New Drug Application (sNDA) Seeks to Add an Indication for Men with Prostate Cancer that Has Spread but Is Sensitive to Hormone Therapy
-
U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review for the Treatment of Men with Metastatic Hormone-Sensitive Prostate Cancer
8/21/2019
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the filing of a supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) to add an indication for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC).
-
Great Place to Work is an organization whose goal it is to assure that all people in the U.S. have a great place to work by 2030. One category for certified companies is Biotechnology & Pharmaceuticals, which listed 36 companies. BioSpace organized these 36 companies into its BioSpace Hotbed Regi...
-
Astellas and Frequency Therapeutics Enter into License Agreement for FX-322, a Regenerative Treatment Candidate for Hearing Loss
7/17/2019
Astellas Obtains the Exclusive Rights to Develop and Commercialize FX-322 in Ex-U.S. Markets; Frequency Retains U.S. Rights
-
Seattle Genetics and Astellas Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
7/16/2019
Submission Based on Pivotal Phase 2 Trial Results Recently Presented at Annual Meeting of American Society of Clinical Oncology
-
Aevi Genomic Medicine Enters into Worldwide License Agreement with Astellas to Develop and Commercialize a Novel Second Generation mTORC1/2 Inhibitor
7/15/2019
Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, "Aevi") today announced it has entered into an exclusive license agreement with OSI Pharmaceuticals, LLC,
-
XOSPATA® (gilteritinib) Available at Biologics by McKesson
12/7/2018
Biologics by McKesson, an independent specialty pharmacy for oncology and other complex therapeutic areas, announced that it has been selected by Astellas Pharma US, Inc. to be in the limited distribution network for XOSPATA® (gilteritinib).
-
220 Employees Chopped as Astellas Winds Down SoCal's Agensys, Inc.
7/28/2017
-
Seattle Genetics And Agensys, Inc., An Affiliate Of Astellas, Highlight Promising Enfortumab Vedotin (ASG-22ME) And ASG-15ME Phase 1 Data In Metastatic Urothelial Cancer At 2016 ESMO Congress
10/7/2016
-
Agensys, Inc. And Sea Lane Biotechnologies, LLC Sign Commercial License Agreement For Antibodies Generated Using ConCIRT Libraries
6/2/2014
-
Seattle Genetics, Inc. and Agensys, Inc., an Affiliate of Astellas Pharma Inc., Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration
6/27/2013
-
Agensys, Inc. and Seattle Genetics, Inc. Announce Interim Phase I Data from ASG-5ME Clinical Trial for Prostate Cancer
6/4/2012